Actively Recruiting

Phase 3
Age: 2Years - 17Years
All Genders
NCT07158242

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Led by Hoffmann-La Roche · Updated on 2026-04-23

100

Participants Needed

9

Research Sites

258 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).

CONDITIONS

Official Title

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Bodyweight >= 10 kilogram (kg)
  • Confirmed diagnosis of ulcerative colitis
  • Intolerance or inadequate response to systemic corticosteroids, immunomodulators, and/or biologic therapies
Not Eligible

You will not qualify if you...

  • Monogenic disorder related to infant onset inflammatory bowel disease
  • Current diagnosis of Crohn's disease, abdominal/intrabdominal/perianal fistula or abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease
  • Presence of an ostomy or ileoanal pouch
  • Current diagnosis or suspicion of primary sclerosing cholangitis
  • Major surgery within 6 weeks prior to screening or planned major surgery during the study
  • Active tuberculosis infection indicated by positive TB test, symptoms, or chest imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30342

Actively Recruiting

2

NYU School of Medicine

New York, New York, United States, 10016

Actively Recruiting

3

National Taiwan University Hospital

Taipei, Taiwan, 100

Actively Recruiting

4

Chulalongkorn University

Bangkok, Thailand, 10330

Actively Recruiting

5

Siriraj Hospital

Bangkok, Thailand, 10700

Actively Recruiting

6

Ramathibodi Hospital

Bangkok, Thailand

Actively Recruiting

7

Birmingham Children's Hospital

Birmingham, United Kingdom, B4 6NH

Actively Recruiting

8

Addenbrooke's Hospital

Cambridge, United Kingdom, CB2 0QQ

Actively Recruiting

9

Sheffield Childrens Hospital

Sheffield, United Kingdom, S10 2TH

Actively Recruiting

Loading map...

Research Team

R

Reference Study ID Number: CA45905 https://forpatients.roche.com/

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis | DecenTrialz